RESUMO
This review forms part of an annual update series on atopic eczema (AE), where systematic reviews (SRs) are gathered and appraised to provide a summary of key recent research findings. The focus of this article is systemic therapies used in AE, while a review on prevention and topical therapies is provided in Part 1. In total, 17 SRs on various systemic treatments used in AE were first published or indexed in 2018. There is a lack of evidence to support vitamin D supplementation, montelukast and naltrexone in AE treatment. The adverse effects of systemic corticosteroids are the main barrier to their use, and there is also a lack of data to determine the optimal delivery and duration of treatment with them. Of other immunosuppressants, ciclosporin has the most robust evidence of efficacy. Biologic therapies in AE treatment are being increasingly investigated, and to date, the greatest quantity of data and evidence of efficacy relates to dupilumab. The most commonly reported adverse effects are injection-site reactions and conjunctivitis. Other biologics showing some evidence of efficacy include nemolizumab, lebrikizumab and tralokinumab, although further data are needed. There are currently insufficient data on oral small molecules, including Janus kinase inhibitors, in the treatment of AE. A Cochrane review on probiotics showed no significant benefit, and SRs and meta-analyses on complementary and alternative medicines, including probiotics, in paediatric AE demonstrated significant heterogeneity, thereby limiting their interpretation. This summary of recent SRs provides up-to-date evidence for clinicians on systemic therapies in AE.
Assuntos
Dermatite Atópica/tratamento farmacológico , Eczema/tratamento farmacológico , Eczema/patologia , Acetatos/administração & dosagem , Acetatos/efeitos adversos , Acetatos/uso terapêutico , Corticosteroides/efeitos adversos , Anticorpos Monoclonais/efeitos adversos , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Humanizados/efeitos adversos , Anticorpos Monoclonais Humanizados/uso terapêutico , Terapia Biológica/efeitos adversos , Terapia Biológica/métodos , Terapia Biológica/estatística & dados numéricos , Criança , Terapias Complementares/efeitos adversos , Terapias Complementares/métodos , Terapias Complementares/estatística & dados numéricos , Ciclopropanos/administração & dosagem , Ciclopropanos/efeitos adversos , Ciclopropanos/uso terapêutico , Ciclosporina/administração & dosagem , Ciclosporina/uso terapêutico , Indutores do Citocromo P-450 CYP1A2/administração & dosagem , Indutores do Citocromo P-450 CYP1A2/efeitos adversos , Indutores do Citocromo P-450 CYP1A2/uso terapêutico , Dermatite Atópica/diagnóstico , Dermatite Atópica/prevenção & controle , Eczema/diagnóstico , Eczema/prevenção & controle , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/uso terapêutico , Inibidores de Janus Quinases/uso terapêutico , Naltrexona/administração & dosagem , Naltrexona/efeitos adversos , Naltrexona/uso terapêutico , Antagonistas de Entorpecentes/administração & dosagem , Antagonistas de Entorpecentes/efeitos adversos , Antagonistas de Entorpecentes/uso terapêutico , Omalizumab/efeitos adversos , Omalizumab/uso terapêutico , Efeito Placebo , Probióticos/efeitos adversos , Probióticos/uso terapêutico , Quinolinas/administração & dosagem , Quinolinas/efeitos adversos , Quinolinas/uso terapêutico , Sulfetos/administração & dosagem , Sulfetos/efeitos adversos , Sulfetos/uso terapêutico , Ustekinumab/efeitos adversos , Ustekinumab/uso terapêuticoRESUMO
Pomalidomide is an immunomodulatory drug, and the dosage of 4 mg per day taken orally on days 1-21 of repeated 28-day cycles has been approved in the European Union and the United States to treat patients with relapsed/refractory multiple myeloma. In vitro data showed that pomalidomide is a substrate of multiple cytochrome P450 (CYP) isozymes and that its oxidative metabolism is mediated primarily by CYP1A2 and CYP3A4, with minor contributions from CYP2C19 and CYP2D6. The effect of CYP1A2 inhibition by fluvoxamine (a strong CYP1A2 inhibitor) and CYP1A2 induction by smoking on pomalidomide pharmacokinetics in healthy subjects has been assessed in 2 separate phase 1 open-label, single-dose studies. Following administration of a single oral dose of 4 mg pomalidomide, the plasma exposure when coadministered with fluvoxamine was 225.1% and 123.7% of that when administered alone for the total plasma exposure (AUC0-inf ) and the plasma peak exposure (Cmax ), respectively. In smokers with elevated CYP1A2 activity demonstrated by high caffeine clearance (a marker of CYP1A2 induction), the AUC0-inf was 32.3% lower, whereas the Cmax was 14.4% higher than that in nonsmokers. In addition, pomalidomide was safe and well tolerated as a single oral dose of 4 mg in healthy male smokers and nonsmokers ≥ 40 to ≤ 80 years old, and a single oral dose of 4 mg pomalidomide coadministered with multiple oral 50-mg doses of the CYP1A2 inhibitor fluvoxamine compared with pomalidomide alone was safe and well tolerated by the healthy male subjects.
Assuntos
Fumar Cigarros , Citocromo P-450 CYP1A2/metabolismo , Interações Medicamentosas , Talidomida/análogos & derivados , Adulto , Idoso , Área Sob a Curva , Cafeína/administração & dosagem , Cafeína/farmacocinética , Cafeína/farmacologia , Indutores do Citocromo P-450 CYP1A2/administração & dosagem , Indutores do Citocromo P-450 CYP1A2/farmacocinética , Indutores do Citocromo P-450 CYP1A2/farmacologia , Inibidores do Citocromo P-450 CYP1A2/administração & dosagem , Inibidores do Citocromo P-450 CYP1A2/farmacocinética , Inibidores do Citocromo P-450 CYP1A2/farmacologia , Fluvoxamina/administração & dosagem , Fluvoxamina/farmacocinética , Fluvoxamina/farmacologia , Meia-Vida , Voluntários Saudáveis , Humanos , Masculino , Pessoa de Meia-Idade , Talidomida/administração & dosagem , Talidomida/farmacocinéticaRESUMO
Dabigatran etexilate is a substrate of the P-glycoprotein (adenosine triphosphate-binding cassette subfamily B member 1) transport system and is subject to interactions with medications that induce or inhibit this system. The clinical relevance of the interaction between dabigatran and phenytoin has not been well described. We report a case of left atrial thrombus in a patient receiving concomitant dabigatran etexilate and phenytoin, which is a P-glycoprotein inducer. This case illustrates the potential clinical significance of the interactions of medications that affect P-glycoprotein and dabigatran.
Assuntos
Dabigatrana/efeitos adversos , Cardiopatias/induzido quimicamente , Fenitoína/efeitos adversos , Trombose/induzido quimicamente , Idoso , Antitrombinas/administração & dosagem , Antitrombinas/efeitos adversos , Indutores do Citocromo P-450 CYP1A2/administração & dosagem , Indutores do Citocromo P-450 CYP1A2/efeitos adversos , Dabigatrana/administração & dosagem , Interações Medicamentosas , Quimioterapia Combinada , Ecocardiografia Transesofagiana , Átrios do Coração , Cardiopatias/diagnóstico , Humanos , Masculino , Fenitoína/administração & dosagem , Embolia Pulmonar/tratamento farmacológico , Trombose/diagnósticoRESUMO
Concurrent administration of oxycodone and phenytoin may cause, through induction of CYP3A4 enzymes, decreased analgesic effects of oxycodone. However, no descriptions of this interaction exist. A patient who was on oxycodone for chronic back pain was admitted to the hospital. Five days after initiating fosphenytoin, the patient experienced a dramatic escalation in his pain and lack of response to oxycodone breakthrough doses. Changing oxycodone to hydromorphone resulted in significantly improved analgesia. Concurrent use of fosphenytoin and oxycodone may increase the conversion of oxycodone to inactive metabolites, resulting in decreased analgesia. This may be avoided using hydromorphone, morphine, or oxymorphone.
Assuntos
Dor Crônica/tratamento farmacológico , Citocromo P-450 CYP3A/metabolismo , Hidromorfona , Oxicodona , Fenitoína , Convulsões/tratamento farmacológico , Adulto , Analgésicos Opioides/administração & dosagem , Analgésicos Opioides/farmacocinética , Dor Crônica/complicações , Dor Crônica/diagnóstico , Indutores do Citocromo P-450 CYP1A2/administração & dosagem , Indutores do Citocromo P-450 CYP1A2/farmacocinética , Relação Dose-Resposta a Droga , Interações Medicamentosas , Substituição de Medicamentos/métodos , Humanos , Hidromorfona/administração & dosagem , Hidromorfona/farmacocinética , Masculino , Oxicodona/administração & dosagem , Oxicodona/farmacocinética , Manejo da Dor/métodos , Medição da Dor , Fenitoína/administração & dosagem , Fenitoína/farmacocinética , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Convulsões/complicações , Resultado do TratamentoRESUMO
PURPOSE: To report the unsafe herb-drug interactions between a commercial product of noni juice and phenytoin in a human case. CASE REPORT: A 49-year-old-male has been treated with phenytoin for epilepsy for more than ten years. In spite of his medication adherence, persistent sub-therapeutic phenytoin levels, which were sometimes from low to undetectable, with the result of having poor seizure control were noted as the noni fruit juice was co-administered daily. The possible mechanism is speculated to be due to noni juiceinduced cytochrome P-450 2C9 metabolism of phenytoin. Owing to many beneficial effects of noni juice, the patient was unwilling to accept our advice to quit taking it. Clobazam treatment was added, and with gradually reducing the amount of juice drunk over six months, the patient's epilepsy has been well controlled. Now only auras along with sometimes minor partial seizures occur, but no major attack has been reported for more than one year. CONCLUSION: Phenytoin had been commonly used for seizure control worldwide and nearly half of patients with epilepsy had received complementary and alternative medicine in Taiwan. Thus, this report is significantly important for clinicians to be aware of the interaction between antiepileptic drugs and some herbs like noni juice. Moreover, as far as we know, this is a rare human case that is reported to disclose this unfavorable herb-drug interaction.